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Lung cancer is the leading cause of cancer-related mortality in
Canada (1) and around the world. Non-small cell lung cancer
(NSCLC) is the most frequent form of lung cancer, accounting
for approximately 87% of cases and the majority of these are
metastatic at the time of presentation (2, 3).
We have reached a plateau (4, 5) with different systemic
chemotherapies, specifically platinum-based, which have been
used to treat metastatic NSCLC for several decades; median sur-
vival improved to 8–10 months (from 4-6 months without treat-
ment). Significant toxicities limited the number of cycles that
could be administered (6).
Current recommendations for first-line treatment of advanced
NSCLC use both histologic and molecular diagnostics in design-
ing the course of treatment (7, 8). We have learned the importance
of distinguishing between squamous and non-squamous histolo-
gies (9) in order to choose an appropriate chemotherapy regimen.
The algorithms for first-line treatment of advanced NSCLC recom-
mend using both histologic and molecular diagnostics in designing
the treatment (7, 10, 11). This in turn requires an adequate amount
of biopsied tumor tissue in order to be able to perform all the nec-
essary testing, which is needed for right decisions (12). Tumor
aspirations for the diagnosis are not acceptable anymore.
Recent advances in understanding signaling pathways for
malignant cells, interconnections in those pathways, the impor-
tance of various receptors (13–15), and biomarkers, and also the
interplay between various oncogenes have led to the development
of targeted treatments that are improving not only the efficacy
of the treatments, but also safety benefits, less toxicity (16) with
improvement of patient’s quality of life (17) in this palliative
setting.
These treatments are aimed at specific (especially genetic) alter-
ations in the malignant cells. Various NSCLC subtypes are associ-
ated with potentially targetable biomarkers such as mutation of the
epidermal growth factor receptors (EGFR) (18–22), KRAS (23), or
the presence of echinoderm microtubule-associated protein-like 4
(EML-4) and anaplastic lymphoma kinase (ALK) fusion genes,
ALK rearrangements (13, 15). C-Met over-expression or amplifi-
cation (24–27), are playing a role in the development of resistance
to the therapies (28), i.e., with EGFR-TKIs. T790M mutation on
Exon 20 in the EGFR domain is the most frequent cause of the
development of this resistance (29).
Knowledge about the advantages of treatments with targeted
agents in advanced NSCLC is rapidly growing, but the hope is to
eventually apply this knowledge to earlier stages of NSCLC and
thus to increase the cure rate of these patients. Combining various
targeted agents or sequencing them properly will be of the utmost
importance in the new era of personalized targeted therapy (30).
Many clinical trials are ongoing to help us make the appropri-
ate decisions how to optimally treat advanced NSCLC in future
(31, 32). Immunotherapy of advanced NSCLC (33) is one of the
exciting areas of research and results of phase III trials are eagerly
awaited.
Contributors in this issue of Frontiers in Thoracic Oncology
describe the importance of team work (34) from diagnosis through
various treatments to supportive care. They explain and empha-
size the importance of the treatments of brain metastases (35) and
bone metastases with new bone targeted agents (36). Management
of adverse events when the new targeted agents are used (16) and
analysis of patients’ health-related quality of life (HR QOL) (17)
and the impact on patients’ performance status (PS) are also dis-
cussed in this issue. It is very important to preserve a good PS of
patients in order to make it possible for them to receive multiple
lines of the treatments now available for advanced NSCLC.
Our review will cover the description starting with the interven-
tional procedures (12), to treatments delivered by radiation oncol-
ogists (37), medical oncologists (10, 11, 34), including descriptions
of ongoing trials to provide a glimpse of the future (31, 32). The
importance of early supportive care (38), which should be an inte-
gral part of active care from the start of treatment of advanced
NSCLC, will also be discussed.
We hope to provide a complete review of present and future
approaches to personalized medicine in advanced NSCLC, reflect-
ing the present views, and practices in Canada.
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